지베렐린 처리가 땅콩 鍾間 交雜 親和性에 미치는 影響

Byoung Ok Ahn(安炳玉),Seok Dong Kim(金石東),Hee Woon Park(朴喜運),Jang Hwan Park(朴長煥),Kwang Ho Kim(金光鎬) 한국육종학회 1994 한국육종학회지 Vol.26 No.4

Interspecific crosses between three peanut cultivars(Arachis hypogaea) having different plant type, and four wild species, Arachis monticola, Arachis correntina, Arachis applisippla, Arachis rigonii were made by gibberellin(GA₃) treatment and the GA₃ effect on the interspecific crossability and growth of pollen tube in pistil was investigated. Pollen germination on the stigma and penetration of the pollen tubes into the style were increased by GA₃ treatment on the flower base. The GA₃ treatment increased pegging and pod formation up to 47% and 1.6% higher than those of control, respectively. Interspecific-crossability was varied with the combination of cultivar and wild species. Combination of Shipung-type variety Daekwangtangkong×wild species and Spanish-type variety Jinpungtangkong×wild species showed about 2% higher crossability than those of Virginia type variety Namdaetangkong×wild species. Arachis monticola among wild species showed the highest crossability with peanut cultivars, while Arachis correntina did the lowest. This result suggested that interspecific crossbility become higher in the cross between autoplyploids rather than those between allopolyploids.

에탄올 - 유발 위점막손상에 대한 애엽추출물 (DA-9601) 의 방어효과 및 기전에 관한 연구

안병옥(Byoung Ok Ahn),김원배(Won Bae Kim),김순회(Soon Hoe Kim),이은방(Eun Bang Lee),오태영(Tae Young Oh),류병권(Byung Kweon Ryu),고준일(Jun Il Ko),손미원(Mi Won Son) 한국응용약물학회 1997 Biomolecules & Therapeutics(구 응용약물학회지) Vol.5 No.2

Protective effect of DA-9601, an extract of Artemisia Herb, against ethanol-induced gastric mucosal injury was evaluated in rats. In the prophylactic study, DA-9601 exhibited total protection (99.4%) against absolute ethanol-induced gastropathy. And the protective effect of DA-9601 lasted up to 2 hours, which was longer than those of other contemporary mucoprotectants. In the treatment study, DA-9601 significantly facilitated the healing of 70% ethanol-induced mucosal damage, which was superior to cetraxate, a commonly used anti-ulcer drug. The mechanisms of mucoprotection of DA-9601 were also assessed. DA9601 increased the release of prostaglandin E₂ from murine neutrophils in a dose-dependent manner in vitro. The cytoprotective effect of DA-9601 against ethanol-induced mucosal damage was significantly diminished by the concommitant injection of N_w-nitro-L-arginine methyl ester (L-NAME, 5 mg/kg, i.v.), a non-specific nitric oxide (NO) synthase inhibitor, while it was not affected by preinjection of indomethacin (5 mg/kg, s.c.), a prostaglandins-depletor. And it was found that DA-9601 significantly enhanced adaptive cytoprotective action of 10% ethanol against absolute ethanol (56.9±6.5 vs 23.0±3.3 mm², p<0.05, mean±SEM), though its exact underlying mechanism remains to be clarified. The present findings demonstrate that DA-9601 exerts gastroprotective actions for the stomach against ethanol through several different underlying mechanisms, in which prostanglandins and NO are involved. In conclusion, the results obtained suggest that DA-9601 can be useful both in prevention and treatment of ethanol-induced gastric damage.

새로운 아드리아마이신유도체 DA-125 의 조혈기독성과 함암효과에 미치는 G-CSF 의 영향

안병옥(Byoung Ok Ahn),김원배(Won Bae Kim),양중익(Junn Ick Yang),이상득(Sang Deuk Lee),류병권(Byung Kweon Ryu) 한국응용약물학회 1997 Biomolecules & Therapeutics(구 응용약물학회지) Vol.5 No.2

The present study was designed to evaluate the effects of a recombinant human granulocytecolony stimulating factor (G-CSF) on leukopenia and tumor growth in mice treated with DA-125, an adriamycin (ADM) derivative. In normal mice, single intravenous injection of DA-125 produced transient leukopenia accompanied with weight loss and splenic atrophy in a dose-related manner. However, subcutaneous administration of G-CSF (5 ㎍/head) for 5 consecutive days after DA-125 resulted in a significantly elevated nadir of leukocyte counts and facilitation of recovery from the leukopenia. To investigate the effect of G-CSF on antitumor effects of DA-125, ADM (12 mg/kg) or DA-125 (40 mg/kg) was administered to Colon-26 murine adenocarcinoma-bearing Balb/c mice with G-CSF. Regardless of treatment with G-CSF, DA125 and ADM markedly retarded the growth of implanted tumor, though they failed to increase mean survival time of tumor-bearing mice. These results suggest that G-CSF is able to not only ameliorate, but reconstitute DA-125-induced myelosuppression without affecting its antitumor potential.

토끼에 대한 천연형인성장호르몬 DA-3002 의 국소작극성

김옥진(Ok Jin Kim),안병옥(Byoung Ok Ahn),이순복(Soon Bok Lee),김원배(Won Bae Kim),양중익(Jung Ick Yang) 한국응용약물학회 1995 Biomolecules & Therapeutics(구 응용약물학회지) Vol.3 No.1

The local irritation studies of DA-3002, an authentic recombinant human growth hormone (rhGH), were carried out in rabbits after the following treatment ; application into the conjunctival sac of the eye (single), single subcutaneous and intramuscular injection, 7-day repeated subcutaneous and intramuscular injection. The results obtained were as follows. In the result of ocular irritation test, 0.16% solution of DA-3002 could be considered as a non-irritating material. In single subcutaneous and intramuscular irritation test, the irritancy of 0.16% DA-3002 solution was not so much different from that of saline. The local irritation of DA-3002 by 7-day repeated injection was negligible and similar to that of saline by both subcutaneous and intramuscular routes. These results suggest that DA-3002 has no irritating activity when injected through subcutaneous or intramuscular route for clinical practice as 0.16% solution.

애엽추출물 항궤양제 DA-9601 의 랫드에 대한 4 주 경구 반복투여 독성연구

김옥진(Ok Jin Kim),강경구(Kyung Koo Kang),김동환(Dong Hwan Kim),백남기(Nam Gi Baik),안병옥(Byoung Ok Ahn),김원배(Won Bae Kim),양중익(Junn Ick Yang) 한국응용약물학회 1996 Biomolecules & Therapeutics(구 응용약물학회지) Vol.4 No.4

This study was conducted to investigate the repeated dose toxicity of DA-9601, an antiulcer agent of Artemisia spp. extract, in rats. DA-9601 was administered orally once a day for 4 weeks to 10 males and 10 females per group at doses of 0(vehicle control), 125, 500 or 2000 mg/kg/day. Throughout the study, no treatment-related deaths and clinical signs were observed. In female rats receiving 125 mg/kg of DA-9601, water consumption increased slightly on day 4, 11 and 25. Hematological examination showed a decrease of MCV and an increase of PLT in male rats at the doses of 500 and 2000 mg/kg groups. Blood biochemistry revealed slight decreases of cholesterol, BUN and Na in male rats and decreases of total bilirubin and creatinine and slight increases of globulin and Cl in female rats. The organ weights at the end of 4 weeks showed slight changes in some organs of treated groups. But, all these changes were not considered to be of toxicological importance, because they did not show dose-response relationship and relevance to gross and microscopic findings. Histopathologically, abnormal treatment-related changes were not observed in any organ and target organs were not detected. On the basis of these results, the NOAEL(no-observed-adverse-effect level) of DA-9601 was estimated to be more than 2000 mg/kg/day under the conditions tested.

천연형 인성장호르몬 DA-3002 의 단회 및 13 주 반봅투여독성연구

김옥진(Ok Jin Kim),강경구(Kyoung Koo Kang),안병옥(Byoung Ok Ahn),이순복(soon Bok Lee),김원배(Won Bae Kim),양중익(Junn Ick Yang),백남기(Nam Gi Baik) 한국응용약물학회 1994 Biomolecules & Therapeutics(구 응용약물학회지) Vol.2 No.2

This study was conducted to examine DA-3002, a biosynthetic human growth hormone, for its acute and subacute toxicities in mice and rats. The drug was administered subcutaneously and orally at a dose level of 1.0, 3.0, 8.9, 26.7 or 80.0 IU/㎏ once for single dose toxicity and given subcutaneously at a dose level of 0.34, 1.7 or 8.4 IU/㎏ daily for 13 weeks to investigate repeated dose toxicity. In the acute toxicity study, doses up to 80 IU/㎏ had no adverse effect on the behavior or body weight gain. Pathological examinations revealed no abnormal changes which could be attributed to toxic effect of DA-3002. In the subacute toxicity study, the growth hormone was tolerated well in both mice and rats. No drug related deaths occurred and all animals appeared to be normal throughout the dosing period. Increases in body weight gain, food utilisation and absolute organ weights were observed in the rats in the high dose group. Mild changes in the blood chemical parameters were also seen in the treated groups. Histopathologically, however, no abnormal changes were observed in any organ. The changes noted during the treatment periods presumably represent exaggerated pharmacological effects of the growth hormone, and no observed adverse effect level (NOAEL) was considered to be more than 8.4 IU/㎏/day.

새로운 괴립구 콜로니 자극인자 ( rhG-CSF ) DA-3030 의 국소자극성에 관한 연구

김옥진(Ok Jin Kim),안병옥(Byoung Ok Ahn),이순복(Soon Bok Lee),김원배(Won Bae Kim),양중익(Jung Ick Yang) 한국응용약물학회 1994 Biomolecules & Therapeutics(구 응용약물학회지) Vol.2 No.3

As a series of safety studies of DA-3030, a new rhG-CSF, its local irritancy was examined in the rabbits after the following treatment; application into the conjunctival sac of the eye(singie), subcutaneous injection(single), intramuscular injection(single), and intravenous injection(8-day repeated). In addition, paravenous irritation of DA-3030 was investigated in mice. The results obtained were as follows. 1. In the result of ocular irritation test, 0.03% solution of DA-3030 could be considered as a non-irritating material. 2. The local irritation of DA-3030 by an injection of 0.5 ml of its solution subcutaneously or intramuscularly was negligible and not so much different from that of saline. 3. In the vascular irritancy test, macro- and microscopic observations revealed that the irritating activity of DA-3030 in blood vessels was not different from that of saline when they were injected once a day into vein retroauricularis of rabbits for 8 days. 4. The paravenous administration of DA-3030 did not induce any abnormal changes at injection sites except mild swelling in 1 mouse at 3 hours after injection which was thought to be due to slow absorption. The above-mentioned results suggest that DA-3030 has no irritating activity when injected through intravenous or subcutaneous route for clinical practice as 0.03% solution.

참깨의 비닐피복 기계화 일관작업 체계 연구

강철환,이병규,안병옥,박충범,노재환,이성우,이승택,홍종태,이선호,김석현,이상철,김완석,Kang, Chul-Whan,Lee, Byoung-Kyu,Ahn, Byoung-Ok,Park, Choong-Bum,Roh, Jae-Hwan,Lee, Seong-Woo,Lee, Seung-Tack,Hong, Jong-Tae,Lee, Sun-Ho,Kim, Seok-Hyeon 한국작물학회 1997 한국작물학회지 Vol.42 No.5

This study was carried out to develop and investigate integrated mechanization system on polyethylene(P.E.) film mulching culture in sesame. Field trials were carried out to develop optimum mechanics for each step of manual operation in sesame culture and demonstrated those developed mechanics of sesame dibbling vinyl mulcher, sesame binder, sesame thresher and sesame grader at the farmer, s field of Hwasong (Kyunggi-do) in 1994 and 1995. Newly developed sesame dibbling vinyl mulcher brought saving manpower 280 hrs /ha for sowing and P.E. film mulching with it's 98% of labour saving for the harvesting operation of sesame. Sesame Binder showed 93% labour saving for cutting and binding with only 22 hrs /ha compared to 330 hrs /ha that of conventional. Sesame thresher was appeared to have 85% effects of labour saving for threshing with completely dry sesame bundles at one time by 23 hrs /ha compared to 151 hrs /ha that of conventional. Sesame grader was appeared to have 72% effects for sesame grain grading with 12 hrs /ha compared to that of conventional 54 hrs /ha. Grain yield of integrated mechanization culture system showed 6% higher than that of coventional. Integrated mechanization culture system (sesame dibbling vinyl mulcher + sesame binder + sesame thresher + sasame grader) showed 62% of labour saving effects through whole steps of sesame culture by 472 hrs /ha compared to that of conventional 1, 230 hrs /ha.

새로운 Authracycline 계 항암성 항생물질 DA-125 의 랫드에 대한 4주 용량설정시험 ( DRF ) 과 13 주 아급성 독성시험

백남기(Nam Gi Baik),안병옥(Byoung Ok Ahn),이순복(soon Bok Lee),이상득(Sang Deuk Lee),김원배(Won Bae Kim),양중익(Jung Ick Yang),(Eric J . F . Spicer),(Susan Novitsky),(Lee Bernal),(Pamela Ball),(Mary Ellen Mckenna),(K . 한국응용약물학회 1994 Biomolecules & Therapeutics(구 응용약물학회지) Vol.2 No.2

This study was conducted to investigate the repeated dose toxicity of DA-125, a new anthracycline antitumor antibiotic, in rats. Before the 13-week main study, a 4-week dose-range finding (DRF) study was carried out. The administration of DA-125 intravenously at dosage levels of 0, 0.125, 0.5, 2.0, and 8.0 ㎎/㎏/day to rats for 4 weeks resulted in premature deaths of all animals in the 8.0 ㎎/㎏/day group and in the deaths of 4 males and 4 females at 2.0 ㎎/㎏/day. Body weights were markedly reduced in the 8.0 ㎎/㎏/day group and showed dose-related decreases in all treatment groups when compared with the control group. Reductions in weight gain were slight and not significantly different at 0.125 ㎎/㎏/day but animals receiving 0.5 ㎎/㎏/day showed more marked decreases in gain in a clear dose-related manner. Based on the results of the above DRF study, a 13-week repeated dose intravenous toxicity study in rats with DA-125 was performed at a dose level of 0, 0.012, 0.08 and 0.3 ㎎/㎏/day. No treatment related effects were noted in behavior or body weight in all treatment groups. One male at the highest dose level died on study day 26, but the death could not be related to test article toxicity. Swelling and scabbing of the ears was present in all of the groups, including the control group. There were no treatment related changes in the hematological, biochemical or urinalysis values in all treatment groups. Thymus weights were significantly reduced in males receiving 0.3 ㎎/㎏/day and they were sligltly, and not significantly, reduced in females of the same group. While there were no associated histological changes. Treatment related necrosis was found in the tail vein (injection site) at 0.08 and 0.3 ㎎/㎏/day. On the basis of these results, the no observed effect level (NOEL) was 0.012 ㎎/㎏/day and the maximum tolerated dose (MTD) was estimated to be more than 0.3 ㎎/㎏/day under the conditions tested.

비 마약성 진통제 DA-5018 의 랫드에 대한 4 주 경구투여 아급성독성

백남기(Nam Gi Baik),안병옥(Byoung Ok Ahn),김원배(Won Bae Kim),양중익(Junn Ick Yang),김옥진(Ok Jin Kim),강경구(Kyung Koo Kang) 한국응용약물학회 1997 Biomolecules & Therapeutics(구 응용약물학회지) Vol.5 No.2

4-week repeated dose toxicity of DA-5O18, a new capsaicin analogue analgesic agent, was examined in SD rats at dosage levels of 0, 0.4, 2, 10 and 50 mg/kg/day. DA-5018 was administered orally to 17 males and 17 females per group at doses of 0, 10 and 50 mg/kg and to 12 males and 12 females per group at doses of 0.4 and 2 mg/kg. After the administration period, 5 males and 5 females at the 0, 10 and 50 mg/kg were placed on withdrawal for 2 weeks. Treatment-related clinical signs were observed at 10 and 50 mg/kg. Clinical signs observed immediately after the administration of DA-5018 were grooming, sedation or depression, lacrimation, ataxia, reddening of extremities and ears, ventral or lateral recumbency, respiratory distress, cyanosis and convulsion. Delayed-type clinical signs including focal scabbing and depilation around nose were also observed 1 or 2 weeks after the start of administrarion of DA-5018. Only at the 50 mg/kg group, corneal opacities, reduced body weight gain (male) and death (male 6/17, female 3/17) were noted. In blood biochemical analysis, serum levels of glucose and triglyceride decreased at 10 and 50 mg/kg. In hematological examination, there were increases in the number of red blood cell, hemoglobin content and percent of hematocrit at 10 and 50 mg/kg. Pulmonary enlargement and hemorrhagic spot, focal scabbing and depilation around nose and corneal opacities were seen at the necropsy of the animals died during the dosing of DA-5018 50 mg/kg. Focal scabbing and depilation arowtd nose were observed in the animals terminally necropsied at doses of 10 and 50 mg/kg. Histopathological examination revealed pulmonary hemorrhage, focal necrosis in the scabbed area, corneal necrosis, fibrosis and neovasculization in the stroma. At 0.4 and 2 mg/kg, there were no significant toxic changes attributable to the administration of DA-5018. In conclusion, target organs following to 4-week repeated dose of DA-5018 in the rat were determined to be lung, skin and eyes. Definite toxic dose and no-observed-adverse-effect-level (NOAEL) were estimated to be 50 and 2 mg/kg/day, respectively.